Catherine Williams Mcgowan RBT

Recommended Articles

• Parents Plan Fundraiser for Son with Muscular Dystrophy

  The Realities of Muscular DystrophyFundraisers and How Differences Are Made in Fundraiser Opportunities For Muscular DystrophyEvery single day, different methods are being employed to assist those with muscular dystrophy. In one recent effort and amazing story of inspiration, a local family from...

• The Reality Behind Juvenile-Onset Fibromyalgia

  Over time, more and more health conditions have been discovered, which has ultimately led to a more informed healthcare system. These breakthroughs have been thanks to a neverending goal of creating more efficient treatment options, which is being done as technology improves and becomes more...

• Risky Surgery Gives Man with Rheumatoid Arthritis Ability to Look Up After Decades

  When Rodney Wente started experiencing pain and discomfort in his lower back, he knew that it couldn’t be good news. He was already dealing with rheumatoid arthritis, an autoimmune condition that caused inflammation all over his body. He was getting older, and his body was beginning to fail. When...

• Ed Asner Discusses Son and Grandson’s Autism

  Seven-time Emmy award-winning actor and voice artist, Ed Asner, admitted that he did not see the signs that his youngest son, Charlie, had autism. The signs that others seemed to have noticed, including difficulty fitting in, lack of empathy, and lack of certain lagging skills. “I really found a...

• Your Risk of a Heart Attack Increases While Grieving

  Mourning the death of a loved one will increase the risk of heart attack in the days immediately following the death of the loved one. The risk is elevated in the month that follows the loss, according to a new study. According to the researchers, this is the first study to see whether grieving can...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...